R&D growth and new blockbusters predicted by report

24 June 2016

The launch of 12 new blockbusters, continued growth in research and development (R&D) and the USA’s Pfizer (NYSE: PFE) overtaking Switzerland’s Novartis (NOVN: VX) as the industry’s biggest company by sales, are all predicted for 2016 by a report on the pharma and biotech sectors suggests.

The EP Vantage Pharma & Biotech 2016 Preview, put together by a team of industry analysts, also predicts that Anglo-Swedish company AstraZeneca (LSE: AZN) will slip to the bottom of the top 10 biggest firms in the industry, and that Humira (adalimumab), an arthritis med marketed by the USA’s AbbVie (NYSE: ABBV), will remain pharma’s best-selling drug.

Abbvie is facing a future battle to retain its exclusivity on Humira, however, and the report expects that the Chicago-based company and AstraZeneca will face the biggest patent risks this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK